---
title: "Moderna/Merck mRNA vaccine intismeran cuts melanoma recurrence risk by 42% with Keytruda"
id: "stat-news-0-stat-after-a-cancer-vaccine-s-first-success-the-race-is-on-to-expand-the-impact"
canonical_url: "https://medichelpline.com/clinical-feed/stat-news-0-stat-after-a-cancer-vaccine-s-first-success-the-race-is-on-to-expand-the-impact"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "STAT News"
source_url: "https://www.statnews.com/2026/10/25/mrna-cancer-vaccine-merck-moderna-esmo-intismeran-next-applications/?utm_campaign=rss"
published_at: "2026-10-25T08:31:01.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Moderna/Merck mRNA vaccine intismeran cuts melanoma recurrence risk by 42% with Keytruda
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/stat-news-0-stat-after-a-cancer-vaccine-s-first-success-the-race-is-on-to-expand-the-impact
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** STAT News
- **Source URL:** [Original Journal Publication](https://www.statnews.com/2026/10/25/mrna-cancer-vaccine-merck-moderna-esmo-intismeran-next-applications/?utm_campaign=rss)
- **Published At:** 2026-10-25T08:31:01.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Investigators reported a positive Phase 3, pivotal trial of a bespoke mRNA cancer vaccine presented at ESMO 2026 in Madrid. - The study combined the individualized mRNA vaccine **intismeran** with Merck’s anti–PD-1 therapy **Keytruda** in patients with **melanoma**. - Data indicated the vaccine-plus-Keytruda arm reduced the risk of recurrence or death by 42% compared with Keytruda alone. - The cohort’s improvement represents the first definitive Phase 3 success for a cancer vaccine after about a century of largely unsuccessful efforts, investigators noted. - Clinical leaders at the meeting — including James Larkin and Vinod Balachandran — commented on potential applicability to other tumor types and the field’s long track record of negative results. - The source did not report detailed trial methodology, dosing schedules, patient eligibility criteria, safety or secondary endpoint data in the excerpt provided. - The story framed immediate questions for clinicians: how to adopt the new regimen in melanoma practice and how broadly such individualized vaccines might be deployed across oncology.
## Clinical Analysis & Structured Key Points
[Skip to Main Content](https://www.statnews.com/2026/10/25/mrna-cancer-vaccine-merck-moderna-esmo-intismeran-next-applications/?utm_campaign=rss#wrapper) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo-white.svg) ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * [Save this story for later](https://www.statnews.com/my-account/saved/) * [Share this article](https://www.statnews.com/2026/10/25/mrna-cancer-vaccine-merck-moderna-esmo-intismeran-next-applications/?utm_campaign=rss) [Clinical trials](https://www.statnews.com/topic/clinical-trials/) [Cancer](https://www.statnews.com/topic/cancer/) [ethics](https://www.statnews.com/topic/ethics/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) My Account * [Settings Complete your personal information for a more tailored experience ](https://www.statnews.com/my-account/) * [Saved Stories](https://www.statnews.com/my-account/saved/) * [Billing](https://www.statnews.com/my-account/billing/) * [Log In](https://www.statnews.com/login/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) Reporting from the frontiers of health and medicine ](https://www.statnews.com/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Public Health](https://www.statnews.com/category/health/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Policy](https://www.statnews.com/category/politics/) * [Science](https://www.statnews.com/category/in-the-lab/) * [First Opinion](https://www.statnews.com/category/first-opinion/) * [STAT+](https://www.statnews.com/topic/stat-plus/) * [Midterms 2026](https://www.statnews.com/midterms-2026-health-care-policy-issues/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) Search * [Log In](https://www.statnews.com/login/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [My Account](https://www.statnews.com/my-account/) My Account * [Settings](https://www.statnews.com/my-account/) * [Saved Stories](https://www.statnews.com/my-account/saved/) * [Billing History](https://www.statnews.com/my-account/billing/) [Home](https://www.statnews.com/) News * [Latest](https://www.statnews.com/latest/) * [Series & Investigations](https://www.statnews.com/stat-series-and-investigations-award-winning-journalism/) * Business * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Health Insurance](https://www.statnews.com/category/insurance/) * [Hospitals](https://www.statnews.com/category/hospitals/) * [Medical Devices](https://www.statnews.com/topic/medical-devices/) * Washington * [Policy](https://www.statnews.com/category/politics/) * [FDA](https://www.statnews.com/topic/fda/) * [NIH](https://www.statnews.com/topic/nih/) * Science * [CRISPR](https://www.statnews.com/topic/crispr/) * [Gene Therapy](https://www.statnews.com/topic/gene-therapy/) * [Neuroscience](https://www.statnews.com/topic/neuroscience/) * Public Health * [Addiction](https://www.statnews.com/topic/addiction/) * [Covid-19](https://www.statnews.com/topic/coronavirus/) * [Abortion](https://www.statnews.com/topic/abortion/) * [Health Disparities](https://www.statnews.com/topic/health-disparities/) * [Infectious Disease](https://www.statnews.com/topic/infectious-disease/) * [Mental Health](https://www.statnews.com/topic/mental-health/) * Disease * [Cancer](https://www.statnews.com/topic/cancer/) * [Cardiovascular Disease](https://www.statnews.com/topic/cardiovascular-disease/) * [Chronic Disease](https://www.statnews.com/topic/chronic-disease/) * [Diabetes](https://www.statnews.com/topic/diabetes/) * [Alzheimer's](https://www.statnews.com/topic/alzheimers/) * [Obesity](https://www.statnews.com/topic/obesity/) * Features * [Health Care Costs](https://www.statnews.com/health-insurance-costs-out-of-pocket-out-of-reach-series/) * [The Deadliest Drug](https://www.statnews.com/alcohol-epidemic-hiding-plain-sight-deadliest-drug-series/) * [Science, Shattered](https://www.statnews.com/american-science-shattered/) [Newsletters](https://www.statnews.com/signup/) [Opinion](https://www.statnews.com/category/first-opinion/) Columns * [Adam Feuerstein](https://www.statnews.com/category/adams-take/) * [Matthew Herper](https://www.statnews.com/category/matts-take/) * [Ed Silverman](https://www.statnews.com/category/pharmalot-view/) [Reports](https://reports.statnews.com/) [E-books](https://www.statnews.com/ebooks/) [Podcasts](https://www.statnews.com/podcasts/) [Tools & Trackers](https://www.statnews.com/trackers/) * [CRISPR Tracker](https://www.statnews.com/feature/crispr/tracker/) * [Breakthrough Device Tracker](https://www.statnews.com/feature/stat-plus/breakthrough-device-designation-fda-tracker/) * [Generative AI Tracker](https://www.statnews.com/feature/stat-plus/generative-ai-health-hospitals-tracker/) * [Obesity Drug Tracker](https://www.statnews.com/2023/09/12/new-weight-loss-drug-tracker-novo-nordisk-eli-lilly/) [Events](https://www.statnews.com/events/) * [Upcoming Events](https://www.statnews.com/events#upcoming-events) * [Summits](https://www.statnews.com/stat-summits/) [Community](https://www.statnews.com/community/) * [STAT Wunderkinds 2026](https://www.statnews.com/wunderkinds/) [Video](https://youtube.com/@Statnews) [Advertise](https://www.statnews.com/advertise/) * [STAT Brand Studio](https://sbs.statnews.com/) What's the word? Test your knowledge with our new weekday mini crossword [ Start solving ](https://www.statnews.com/stat-mini-crossword/) [STAT Plus](https://www.statnews.com/stat-plus/)[In the Lab](https://www.statnews.com/category/in-the-lab/) # After a cancer vaccine’s first success, the race is on to expand the impact ## The positive Phase 3 melanoma study comes after 100 years of ‘bad news’ * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * [Save this story for later](https://www.statnews.com/my-account/saved/) * [Share this article](https://www.statnews.com/2026/10/25/mrna-cancer-vaccine-merck-moderna-esmo-intismeran-next-applications/?utm_campaign=rss) ![](https://www.statnews.com/wp-content/uploads/2026/10/IMG_5891-645x645.jpg) The first successful Phase 3 trial of a cancer vaccine was presented at ESMO’s 2026 conference in Madrid.Andrew Joseph/STAT ![](https://www.statnews.com/wp-content/uploads/2021/02/andrew-j-avatar-small-1-80x80.png) By [Andrew Joseph](https://www.statnews.com/staff/andrew-joseph/) Oct. 25, 2026 Europe Correspondent ![](https://www.statnews.com/wp-content/uploads/2021/02/andrew-j-avatar-small-1-80x80.png) [Andrew Joseph](https://www.statnews.com/staff/andrew-joseph/) 1. [](https://x.com/DrewQJoseph "X") andrew.joseph@statnews.com Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. MADRID — With[ the first pivotal trial ](https://www.statnews.com/2026/10/22/esmo-moderna-merck-cancer-vaccine-intismeran-data-released/)showing a customized mRNA treatment improved outcomes for cancer patients presented here this weekend, the conversation has already turned to how melanoma specialists should adopt the medicine — and [how widely ](https://www.statnews.com/2026/10/23/moderna-merck-melanoma-cancer-vaccine-data-arrived-early-esmo/)these novel vaccines can be deployed. “In principle, this type of approach may be applicable to other types of tumors,” James Larkin of London’s Royal Marsden Hospital, the scientific co-chair for this year’s European Society for Medical Oncology meeting, said at an opening press conference. Advertisement The trial, from Merck and Moderna, demonstrated that the bespoke mRNA-based vaccine intismeran reduced the risk of recurrence or death by 42% when combined with Merck’s checkpoint inhibitor Keytruda versus Keytruda alone. The results are a clear victory for the field after what Vinod Balachandran of Memorial Sloan Kettering Cancer Center called in a lecture a “long and sordid” history of trying to develop cancer vaccines that, until now, has essentially added up to 100 years of failure. STAT+ Exclusive Story Already have an account? [Log in](https://www.statnews.com/login/) ![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-breaker-bg.png) [ ![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-logo-white.svg) ](https://www.statnews.com/stat-plus/) ## This article is exclusive to STAT+ subscribers ### Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? [Log in](https://www.statnews.com/login/) Individual plans Group plans Monthly $39 Totals $468 per year [$39/month](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-monthly-39-0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-monthly-39-0) Totals $468 per year Starter $30 for 3 months, then $399/year [$30 for 3 months](https://www.statnews.com/stat-plus/subscribe/?plan=3mo30_yearly_pw) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=3mo30_yearly_pw) Then $399/year Annual $399 Save 15% [$399/year](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-annually-399-0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-annually-399-0) Save 15% 11+ Users Custom Savings start at 25%! [Request A Quote](https://www.statnews.com/stat-plus/group-subscriptions/) [Request A Quote](https://www.statnews.com/stat-plus/group-subscriptions/) Savings start at 25%! 2-10 Users $300 Annually per user [$300/year](https://www.statnews.com/stat-plus/subscribe/?plan=stat_plus_groups_self_serve_0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat_plus_groups_self_serve_0) $300 Annually per user [View All Plans](https://www.statnews.com/stat-plus/) [![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-logo.svg)](https://www.statnews.com/stat-plus/) To read the rest of this story subscribe to STAT+. [Subscribe](https://www.statnews.com/stat-plus/) [Log In](https://www.statnews.com/login/) [biotechnology](https://www.statnews.com/topic/biotechnology/), [Cancer](https://www.statnews.com/topic/cancer/), [drug development](https://www.statnews.com/topic/drug-development/), [STAT+](https://www.statnews.com/topic/stat-plus/) [Submit a correction request](https://www.statnews.com/contact/?how_can_we_help_=Editorial%20Correction%20Request)[Reprints](https://www.parsintl.com/publications/stat/) 1. ![](https://www.statnews.com/wp-content/uploads/2021/02/andrew-j-avatar-small-1-80x80.png) [Andrew Joseph](https://www.statnews.com/staff/andrew-joseph/) 1. [](https://x.com/DrewQJoseph "X") 2. Europe Correspondent 1. [](https://x.com/DrewQJoseph "X") 2. Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. ![](https://www.statnews.com/wp-content/themes/stat/images/article-new/envelope-open.svg) ![](https://www.statnews.com/wp-content/uploads/2023/06/Morning-Rounds-Logo-Black-640x295.png) ### Newsletter Understand how science, health policy, and medicine shape the world every day Please enter a valid email address. Sign Up Your data will be processed in accordance with our [Privacy Policy](https://www.statnews.com/privacy/) and [Terms of Service](https://www.statnews.com/terms-conditions/). You may opt out of receiving STAT communications at any time. Advertisement Most Popular 1. ![](https://www.statnews.com/wp-content/uploads/2026/10/AdobeStock_1846705681_Editorial_Use_Only-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Patient dies in Bristol Myers Squibb autoimmune CAR-T trial](https://www.statnews.com/2026/10/23/bristol-myers-squibb-car-t-therapy-autoimmune-trial-death/) 2. ![](https://www.statnews.com/wp-content/uploads/2017/11/30805878966_8c941bf211_o-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Novartis multiple sclerosis treatment cuts rates of relapse in pivotal trials](https://www.statnews.com/2026/10/23/novartis-remibrutinib-multiple-sclerosis-trial-results/) 3. ![](https://www.statnews.com/wp-content/uploads/2026/10/https___cdn.sanity.io_images_xq1bjtf4_production_964fa47326a827f12bf336e880b2fdc4665711e6-5973x4480-1-80x80.jpg) [I was a Theranos whistleblower. In ‘You Can See Everything,’ Elizabeth Holmes is still lying](https://www.statnews.com/2026/10/19/elizabeth-holmes-theranos-whistleblower-tyler-shultz-insider-review/) 4. ![](https://www.statnews.com/wp-content/uploads/2026/10/AdobeStock_499879090-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Tango reports 82% tumor response rate in trial of combo therapy for advanced pancreatic cancer](https://www.statnews.com/2026/10/23/esmo-2026-trial-results-tango-therapeutics-vopimetostat-revolution-medicines-rasonque/) 5. ![](https://www.statnews.com/wp-content/uploads/2026/10/Header-Final-7-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Does Isomorphic Labs have what it takes to revolutionize drugmaking?](https://www.statnews.com/2026/10/19/can-isomorphic-labs-revolutionize-drugmaking/) #### [ Reports ](https://reports.statnews.com/) [ ![](https://www.statnews.com/wp-content/uploads/2026/08/2026_CancerReport_ReportCover-328x424.jpg) Explore Cancer’s transformational moments: KRAS, CAR-T, immunotherapy, and more ](https://reports.statnews.com/products/cancer-transformational-moments-advances-in-kras-car-t-immunotherapy) Advertisement #### [Events](https://www.statnews.com/events/) [ ![](https://www.statnews.com/wp-content/uploads/2026/09/TevaPF_Wordpress_CalendarImage-80x80.jpg) The Next Era of Biosimilars: Rewriting the Playbook Virtual Oct 19 ](https://www.statnews.com/event/next-era-of-biosimilars-rewriting-the-playbook/) [ ![](https://www.statnews.com/wp-content/uploads/2026/09/ESMORecap_Wordpress_CalendarImage-80x80.jpg) ESMO 2026: The STAT Recap Virtual Oct 29 ](https://www.statnews.com/event/esmo-2026-the-stat-recap/) [ ![](https://www.statnews.com/wp-content/uploads/2026/09/2026ASH_Wordpress_CalendarImage-80x80.jpg) STAT@ASH: Medicine’s Bleeding Edge New Orleans, LA Dec 13 ](https://www.statnews.com/event/stat-at-ash-meeting-2026/) Most Read in [STAT+](https://www.statnews.com/stat-plus/) 1. ![](https://www.statnews.com/wp-content/uploads/2026/10/AdobeStock_1846705681_Editorial_Use_Only-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Patient dies in Bristol Myers Squibb autoimmune CAR-T trial](https://www.statnews.com/2026/10/23/bristol-myers-squibb-car-t-therapy-autoimmune-trial-death/) 2. ![](https://www.statnews.com/wp-content/uploads/2025/05/AdobeStock_525738206_Editorial_Use_Only-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Detailed data confirm Moderna and Merck cancer vaccine met key endpoints in melanoma trial](https://www.statnews.com/2026/10/22/esmo-moderna-merck-cancer-vaccine-intismeran-data-released/) 3. ![](https://www.statnews.com/wp-content/uploads/2026/10/AdobeStock_499879090-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Tango reports 82% tumor response rate in trial of combo therapy for advanced pancreatic cancer](https://www.statnews.com/2026/10/23/esmo-2026-trial-results-tango-therapeutics-vopimetostat-revolution-medicines-rasonque/) 4. ![](https://www.statnews.com/wp-content/uploads/2025/07/GLP1-48-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Telehealth leapfrogs FDA approval with off-label GLP-1 prescriptions for addiction](https://www.statnews.com/2026/10/22/glp-1-drugs-substance-use-disorder-telehealth-off-label-prescription/) 5. ![](https://www.statnews.com/wp-content/uploads/2026/10/GettyImages-2263715743-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Mark Cuban wants to crack open the market for rare disease treatments](https://www.statnews.com/2026/10/21/mark-cuban-cost-plus-drugs-rare-disease-medicines/) #### Recommended ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Biotech Biotech October 24, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: The ESMO presentation everyone’s been waiting for ](https://www.statnews.com/2026/10/24/the-esmo-2026-merck-moderna-presentation-amgen-imdelltra-news/) By [Andrew Joseph](https://www.statnews.com/staff/andrew-joseph/) and [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) First Opinion First Opinion October 24, 2026 ### [ Christina Applegate puts a face on one of the most consequential challenges in neurology ](https://www.statnews.com/2026/10/24/christina-applegate-multiple-sclerosis-why-ms-misdiagnosis-happens/) By Bruce Bebo Advertisement ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) First Opinion First Opinion October 24, 2026 ### [ STAT readers on Elizabeth Holmes, cancer screening, and more ](https://www.statnews.com/2026/10/24/you-can-see-everything-stat-letters-to-editor/) By [Torie Bosch](https://www.statnews.com/staff/torie-bosch/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Biotech Biotech October 23, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Highly anticipated Moderna-Merck melanoma cancer vaccine data arrived early ](https://www.statnews.com/2026/10/23/moderna-merck-melanoma-cancer-vaccine-data-arrived-early-esmo/) By [Andrew Joseph](https://www.statnews.com/staff/andrew-joseph/) and [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Health Health October 23, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Diabetes association says ‘threat’ preceded members’ ejections, but admits policies were unclear ](https://www.statnews.com/2026/10/23/ada-new-orleans-convention-new-report-on-controversial-june-ejections/) By [Elizabeth Cooney](https://www.statnews.com/staff/elizabeth-cooney/) #### Subscriber Picks 1. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: How the No Surprises Act’s nonprofit arbitrators are operating like 'mini gods' and getting rich doing it ](https://www.statnews.com/2026/10/19/no-surprises-act-billing-arbitration-profits-stat-investigation/) By [Tara Bannow](https://www.statnews.com/staff/tara-bannow/) 2. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Does Isomorphic Labs have what it takes to revolutionize drugm
## Related Clinical Research

- [Understanding the Complexity of Multiple Sclerosis Diagnosis: Lessons from Christina Applegate](https://medichelpline.com/clinical-feed/stat-news-0-opinion-christina-applegate-puts-a-face-on-one-of-the-most-consequential.md)
- [Patient death reported in Bristol Myers Squibb CAR-T trial for multiple sclerosis](https://medichelpline.com/clinical-feed/stat-news-2-stat-patient-dies-in-bristol-myers-squibb-autoimmune-car-t-trial.md)
- [Personalized mRNA vaccine plus pembrolizumab lowers melanoma recurrence in phase 3 trial](https://medichelpline.com/clinical-feed/medical-news-today-0-novel-mrna-vaccine-plus-immunotherapy-reduces-melanoma-relapse-in-phase-3-trial.md)
- [Link Between Daily Sugary Drink Consumption and Increased Stomach Cancer Risk](https://medichelpline.com/clinical-feed/medical-news-today-1-daily-sugary-drink-consumption-linked-to-more-than-double-stomach-cancer-risk.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.